Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.41 |
| ▸ | CNR2 | P34972 | 10/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535578 | 0.88 | ESR1 (0.55) | ESR1ARESR2TDP1 | |
| SCHEMBL6828564 | 0.83 | CNR1 (0.44) | CNR1CNR2ESR1ARESR2 | |
| SCHEMBL5890020 | 0.79 | ALDH1A1 (0.50) | CNR1CNR2ALDH1A1ALOX15TSHR | |
| SCHEMBL4401972 | 0.78 | ESR1 (0.52) | CNR1CNR2ESR1ARESR2 | |
| SCHEMBL13096081 | 0.77 | SHBG (0.57) | CNR1CNR2ESR1ARESR2 | |
| SCHEMBL6823441 | 0.76 | SHBG (0.55) | ESR1ARESR2ALDH1A1HPGD | |
| SCHEMBL6828613 | 0.76 | ALDH1A1 (0.50) | ARALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4963369 | 0.75 | CYP19A1 (0.40) | CNR1CNR2ALDH1A1TSHR | |
| SCHEMBL674323 | 0.73 | ALDH1A1 (0.67) | ESR1ARESR2ALDH1A1HPGD | |
| SCHEMBL13204224 | 0.73 | ESR1 (0.71) | CNR1CNR2ESR1ARESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040230073-A1 | Process for production of aspartame derivative, crystal thereof, novel production intermediate therefor, and process for production of intermediate thereof | AJINOMOTO CO., INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20020132032-A1 | Process for production of aspartame derivative, crystal thereof, novel production intermediate therefor, and process for production of intermediate thereof | AJINOMOTO CO., INC. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1219633-A1 | PROCESS FOR PRODUCING ASPARTAME DERIVATIVE, CRYSTALS THEREOF, NOVEL PRODUCTION INTERMEDIATES THEREFOR AND PROCESS FOR PRODUCING THE INTERMEDIATE | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230073-A1 | Process for production of aspartame derivative, crystal thereof, novel production intermediate therefor, and process for production of intermediate thereof | IAPP, DPP4, SI | CNR1 4741/4885CNR2 4776/4885ESR1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.